BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

517 related articles for article (PubMed ID: 36998426)

  • 1. Molecular mechanisms targeting drug-resistance and metastasis in colorectal cancer: Updates and beyond.
    Al Bitar S; El-Sabban M; Doughan S; Abou-Kheir W
    World J Gastroenterol; 2023 Mar; 29(9):1395-1426. PubMed ID: 36998426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current and future targets and therapies in metastatic colorectal cancer.
    Dzunic M; Petkovic I; Cvetanovic A; Vrbic S; Pejcic I
    J BUON; 2019; 24(5):1785-1792. PubMed ID: 31786838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted therapy in colorectal cancer: current status and future challenges.
    Koutras AK; Starakis I; Kyriakopoulou U; Katsaounis P; Nikolakopoulos A; Kalofonos HP
    Curr Med Chem; 2011; 18(11):1599-612. PubMed ID: 21428886
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer.
    Lee SY; Oh SC
    Biomed Res Int; 2016; 2016():7590245. PubMed ID: 27127793
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
    Mitchell EP
    Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNAs as novel predictive biomarkers and therapeutic targets in colorectal cancer.
    Stiegelbauer V; Perakis S; Deutsch A; Ling H; Gerger A; Pichler M
    World J Gastroenterol; 2014 Sep; 20(33):11727-35. PubMed ID: 25206276
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Role of targeted agents in metastatic colorectal cancer.
    Prenen H; Vecchione L; Van Cutsem E
    Target Oncol; 2013 Jun; 8(2):83-96. PubMed ID: 23645285
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging tyrosine kinase inhibitors for the treatment of metastatic colorectal cancer.
    Matos I; Elez E; Capdevila J; Tabernero J
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):267-82. PubMed ID: 27578253
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Strategies in Diseases of the Digestive Tract - 2015 and Beyond Targeted Therapies in Colon Cancer Today and Tomorrow.
    Pohl M; Schmiegel W
    Dig Dis; 2016; 34(5):574-9. PubMed ID: 27332557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeted therapy in advanced metastatic colorectal cancer: current concepts and perspectives.
    Hohla F; Winder T; Greil R; Rick FG; Block NL; Schally AV
    World J Gastroenterol; 2014 May; 20(20):6102-12. PubMed ID: 24876732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting BRAF in metastatic colorectal cancer: Maximizing molecular approaches.
    Strickler JH; Wu C; Bekaii-Saab T
    Cancer Treat Rev; 2017 Nov; 60():109-119. PubMed ID: 28946014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets.
    Martini G; Troiani T; Cardone C; Vitiello P; Sforza V; Ciardiello D; Napolitano S; Della Corte CM; Morgillo F; Raucci A; Cuomo A; Selvaggi F; Ciardiello F; Martinelli E
    World J Gastroenterol; 2017 Jul; 23(26):4675-4688. PubMed ID: 28765689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor: pathway, therapies, and pipeline.
    Goffin JR; Zbuk K
    Clin Ther; 2013 Sep; 35(9):1282-303. PubMed ID: 24054705
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Translational research of new developments in targeted therapy of colorectal cancer.
    Yang L; Atakhanova N; Arellano MTC; Mohamed MY; Hani T; Fahdil AA; Castillo-Acobo RY; Juyal A; Hussein AK; Amin AH; Pecho RDC; Akhavan-Sigari R
    Pathol Res Pract; 2023 Dec; 252():154888. PubMed ID: 37948996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting Angiogenic Pathways in Colorectal Cancer: Complexities, Challenges and Future Directions.
    Khan K; Cunningham D; Chau I
    Curr Drug Targets; 2017; 18(1):56-71. PubMed ID: 25808652
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients.
    Ruzzo A; Graziano F; Canestrari E; Magnani M
    Curr Cancer Drug Targets; 2010 Feb; 10(1):68-79. PubMed ID: 20088793
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasticity of Resistance and Sensitivity to Anti-Epidermal Growth Factor Receptor Inhibitors in Metastatic Colorectal Cancer.
    Sartore-Bianchi A; Siena S
    Handb Exp Pharmacol; 2018; 249():145-159. PubMed ID: 28382467
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the EGFR signalling pathway in metastatic colorectal cancer.
    Napolitano S; Martini G; Ciardiello D; Del Tufo S; Martinelli E; Troiani T; Ciardiello F
    Lancet Gastroenterol Hepatol; 2024 Jul; 9(7):664-676. PubMed ID: 38697174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to anti-EGFR therapies in metastatic colorectal cancer: underlying mechanisms and reversal strategies.
    Zhou J; Ji Q; Li Q
    J Exp Clin Cancer Res; 2021 Oct; 40(1):328. PubMed ID: 34663410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF in metastatic colorectal cancer: the future starts now.
    Orlandi A; Calegari A; Inno A; Berenato R; Caporale M; Niger M; Bossi I; Di Bartolomeo M; de Braud F; Pietrantonio F
    Pharmacogenomics; 2015 Dec; 16(18):2069-81. PubMed ID: 26615988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.